1 |
Mol MJ, Stuyt PM, Stalenhoef AF, van 't Laar A. Cholesterol synthesis inhibitors in hyperlipidaemia. Lancet 1988; 1: 597.
|
2 |
Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1988; 1: 611-3.
|
3 |
Bard JM, Luc G, Douste-Blazy P, et al., Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. Eur J Clin Pharmacol 1989; 37: 545-50.
DOI
|
4 |
Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31.
DOI
ScienceOn
|
5 |
Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988; 109 :682-3.
DOI
ScienceOn
|
6 |
Corpier CL, Jones PH, Suki WN, et al., Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. Jama 1988; 260: 239-41.
DOI
ScienceOn
|
7 |
Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. Jama 1997; 277: 296-7.
|
8 |
Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-5.
DOI
ScienceOn
|
9 |
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-30.
DOI
ScienceOn
|
10 |
Becquemont L. [Drug interactions with antilipemics]. Therapie 2003; 58: 85-90.
DOI
ScienceOn
|
11 |
Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol 1999; 19: 411-5.
DOI
ScienceOn
|
12 |
Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46: 681-96.
DOI
ScienceOn
|
13 |
Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci; 99: 486-514.
|
14 |
Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70.
|
15 |
Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63: 769-802.
DOI
ScienceOn
|
16 |
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol; 32: 675-703.
|
17 |
Olsson AG, Rossner S, Walldius G, Carlson LA. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med 1976; 69 Suppl 2: 28-31.
|
18 |
Betteridge DJ, Higgins MJ, Galton DJ. Properties of sterol biosynthesis in human leukocytes: effects of gemfibrozil. Proc R Soc Med 1976; 69 Suppl 2: 104-6.
|
19 |
Armitage J, Bowman L, Wallendszus K, et al., Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet; 376: 1658-69.
|
20 |
Knoll RW, Ciafone R, Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Conn Med 1993; 57: 593-4.
|
21 |
Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26.
DOI
ScienceOn
|
22 |
Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9.
DOI
ScienceOn
|
23 |
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81.
DOI
ScienceOn
|
24 |
Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56: 120-4.
DOI
ScienceOn
|
25 |
Franson JC. Enzyme activities in plasma, liver and kidney of black ducks and mallards. J Wildl Dis 1982;18: 481-5.
DOI
|
26 |
Dianzani MU. [Distribution of lactic acid oxidase in liver and kidney cells of normal rats and rats with fatty degeneration of the liver]. Arch Fisiol 1951 ;50 :181-6.
|
27 |
Barchetta I, Angelico F, Del Ben M, et al., Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med; 9: 85.
|
28 |
Figueroa RB, Klotz AP. The Effect of Whiskey and Low-Protein Diets on Hepatic Enzymes in Rats. Am J Dig Dis 1964; 9 :121-7.
DOI
ScienceOn
|
29 |
Hofmann AF, Korman MG, Krugman S. Sensitivity of serum bile acid assay for detection of liver damage in viral hepatitis type B. Prospective study in five patients. Am J Dig Dis 1974; 19 :908-10.
DOI
ScienceOn
|
30 |
Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003; 89: 949-50.
|
31 |
Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009; 29: 744-8.
DOI
ScienceOn
|
32 |
Keech A, Collins R, MacMahon S, et al., Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
DOI
ScienceOn
|
33 |
Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992; 340: 979-80.
|
34 |
Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990; 98: 1041-2.
|
35 |
Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602.
DOI
ScienceOn
|